Medical History, Medication Use, and Risk of Nasopharyngeal Carcinoma.
Xiling Xiao,Zhe Zhang,Ellen T. Chang,Zhiwei Liu,Qing Liu,Yonglin Cai,Guomin Chen,Qi-Hong Huang,Shang-Hang Xie,Su-Mei Cao,Jian-Yong Shao,Wei-Hua Jia,Yuming Zheng,Jian Liao,Yufeng Chen,Longde Lin,Ingemar Ernberg,Guangwu Huang,Yi Zeng,Yi-Xin Zeng,Hans-Olov Adami,Weimin Ye
DOI: https://doi.org/10.1093/aje/kwy095
2018-01-01
American Journal of Epidemiology
Abstract:Because persistent inflammation may render the nasopharyngeal mucosa susceptible to carcinogenesis, chronic ear-nose-throat (ENT) disease and its treatment might influence the risk of nasopharyngeal carcinoma (NPC). Existing evidence is, however, inconclusive and often based on methodologically suboptimal epidemiologic studies. In a population-based case-control study in southern China, we enrolled 2,532 persons with NPC and 2,597 controls, aged 20-74 years, from 2010 to 2014. Odds ratios were estimated for associations between NPC risk and history of ENT and related medications. Any history of chronic ENT disease was associated with a 34% increased risk of NPC. Similarly, use of nasal drops or aspirin was associated with approximately doubled risk of NPC. However, in secondary analyses restricted to chronic ENT diseases and related medication use at least 5 years prior to diagnosis/interview, most results were statistically nonsignificant, except a history of uncured ENT diseases, untreated nasal polyps, and earlier age at first diagnosis of ENT disease and first or most recent aspirin use. Overall, these findings suggest that ENT disease and related medication use are most likely early indications rather than causes of NPC, although the possibility of a modestly increased NPC risk associated with these diseases and related medications cannot be excluded.